Indication

Mucopolysaccharidosis type VII

Mucopolysaccharidosis type VII, also known as Sly syndrome, is an extremely rare, progressive autosomal recessive lysosomal storage disease caused by a deficiency of the enzyme beta-glucuronidase. Read more about Mucopolysaccharidosis type VII

1 drugs 1 manufacturers

Advertisement

Drugs that treat it

Common Mucopolysaccharidosis type VII therapies.

Showing 1–1 of 1 drugs

Filter & compare in the drug finder →Opens the drug finder with Mucopolysaccharidosis type VII preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Mucopolysaccharidosis type VII.

Mucopolysaccharidosis type VII, also known as Sly syndrome, is an extremely rare, progressive autosomal recessive lysosomal storage disease caused by a deficiency of the enzyme beta-glucuronidase.

This enzymatic defect prevents the degradation of glycosaminoglycans, leading to pathological substrate accumulation across multiple organ systems, including the skeleton, central nervous system, heart, liver, and spleen.

Clinical manifestations range in severity from fatal non-immune hydrops fetalis in utero to attenuated childhood- or adult-onset forms characterized by skeletal dysplasia (dysostosis multiplex), short stature, hepatosplenomegaly, coarse facial features, corneal clouding, cardiac valve abnormalities, and variable intellectual impairment.

Personalize your experience

Follow Mucopolysaccharidosis type VII and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it